Drugs / Adderall XR
Adderall XR
also known as
MAS-XR · Mixed Amphetamine Salts · amphetamine · ER-MAS · Extended-Release Mixed Amphetamine Salts (Adderall-XR) · MAS · mixed salts amphetamine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00746733 | Sep → Oct 2008 | — | Shire | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00069927 | Aug 2003 → Jun 2006 | childhood malignant neoplasm, depressive disorder, poisoning | University of South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02803229 | Jul 2016 → Jun 2020 | attention deficit-hyperactivity disorder, cannabis dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00553319 | Dec 2007 → Jul 2013 | attention deficit-hyperactivity disorder, cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00507065 | May 2003 → Mar 2004 | attention deficit-hyperactivity disorder | Shire | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT02566824 | Oct 2010 → Aug 2020 | attention deficit-hyperactivity disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 0 | NCT04509102 Comparator | Sep 2021 → Dec 2027 expected | major depressive disorder | University of California, Los Angeles | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05650775 Comparator | Feb 2023 → Mar 2024 | attention deficit-hyperactivity disorder | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00421603 Comparator | Feb 2007 → May 2010 | cocaine dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00557011 Comparator | Sep → Dec 2004 | attention deficit-hyperactivity disorder | New River Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT02676739 Comparator | May 2016 → Nov 2024 overdue | multiple sclerosis | Sarah Morrow | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01667484 Comparator | Sep 2012 → Feb 2013 | cognitive impairment with or without cerebellar ataxia, multiple sclerosis, specific learning disability | London Health Sciences Centre | Completed | No outcome recorded |
| — | NCT02210728 Comparator | Apr 2006 → Oct 2018 | attention deficit-hyperactivity disorder | Lily Hechtman | Unknown | No outcome recorded |
Press releases naming this drug 12 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adderall XR | “Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression” NCT00069927 ↗14“Adderall XR (n=15) versus placebo (n=15)” NCT04509102 ↗ “Adderall XR” NCT02566824 ↗ “Adderall XR” NCT02210728 ↗ |
| Known as | amphetamine | “one 15 mg pill once daily of Adderall XR (amphetamine)” NCT04509102 ↗ |
| Known as | ER-MAS | “Adderall-XR (ER-MAS)” NCT00421603 ↗ |
| Known as | Extended-Release Mixed Amphetamine Salts (Adderall-XR) | “Extended-Release Mixed Amphetamine Salts (Adderall-XR)” NCT00553319 ↗ |
| Known as | MAS | “examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children and to mixed amphetamine salts (MAS; Adderall-XR) among...” NCT05650775 ↗ |
| Known as | MAS-XR | “This study's lead PI recently completed a pre-post dose study with a mixed amphetamine salts formulation with an extended release delivery system (MAS-XR), trade name Adderall...” NCT02676739 ↗1“Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR)” NCT02803229 ↗ |
| Known as | Mixed Amphetamine Salts | “examining pre-treatment EEG and ERP biomarkers of response to methylphenidate (MPH; Concerta) among all children and to mixed amphetamine salts (MAS; Adderall-XR) among...” NCT05650775 ↗1“Mixed Amphetamine Salts (Adderall-XR)” NCT00421603 ↗ |
| Known as | mixed salts amphetamine | “Adderall XR (mixed salts amphetamine)” NCT00746733 ↗ |
| Route | Oral | “Patients receive oral dextroamphetamine-amphetamine once daily for 3 weeks” NCT00069927 ↗ |